Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in São Paulo, Brazil, 1995-2003

Diagnostic Microbiology and Infectious Disease

Volumn 57, Issue 4, 2007, Pages 399-404

  da Matta, Daniel Archimedes ^a   de Almeida, Leila Paula ^a   Machado, Antônia Maria ^a   Azevedo, Ana Carolina ^a   Kusano, Elisa Junko Ura ^b   Travassos, Norma Fracalanza ^c   Salomão, Reinaldo ^a,d   Colombo, Arnaldo Lopes ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

^c HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

^d Hospital e Maternidade Santa Marcelina   (Brazil)

Author keywords

Antifungal susceptibility testing; Candida spp.; Candidemia; Resistance

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ARTICLE; BRAZIL; BROTH MICRODILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDEMIA; CLINICAL TRIAL; FUNGUS ISOLATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; AZOLES; BRAZIL; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FUNGEMIA; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 33947672986     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.10.011     Document Type: Article

References (34)

1. Antunes A.G., Pasqualotto A.C., Diaz M.C., d'Azevedo P.A., and Severo L.C. Candidemia in a Brazilian tertiary care hospital: species distribution and antifungal susceptibility patterns. Rev. Inst. Med. Trop. Sao Paulo 46 (2004) 239-241
2. Aquino V.R., Lunardi L.W., Goldani L.Z., and Barth A.L. Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil. Braz. J. Infect. Dis. 9 (2005) 411-418
3. Arthington-Skaggs B.A., Warnock D.W., and Morrison C.J. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 44 (2000) 2081-2085
4. Cheng M.F., Yu K.W., Tang R.B., Fan Y.H., Yang Y.L., Hsieh K.S., Ho M., and Lo H.J. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn. Microbiol. Infect. Dis. 48 (2004) 33-37
5. Colombo A.L., Nucci M., Salomão R., Branchini M.L.M., Richtmann R., Derossi A., and Wey S. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn. Microbiol. Infect. Dis. 34 (1999) 281-286
6. Colombo A.L., Melo A.S., Crespo Rosas R.F., Salomão R., Briones M., Hollis R.J., Messer S.A., and Pfaller M.A. Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn. Microbiol. Infect. Dis. 46 (2003) 253-257
7. Colombo A.L., Nucci M., Park B.J., Nouer S.A., Arthington-Skaggs B., da Matta D.A., Warnock D., and Morgan J. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J. Clin. Microbiol. 44 (2006) 2816-2823
8. Costa S.F., Marinho I., Araújo E.A.P., Manrique A.E.I., Medeiros E.A.S., and Levin A.S. Nosocomial fungaemia: a 2-year prospective study. J. Infect. Dis. 45 (2000) 69-72
9. Chryssanthou E. Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A reference method. J. Clin. Microbiol. 39 (2001) 4181-4183
10. Cuenca-Estrella M., Rodriguez D., Almirante B., Morgan J., Planes A.M., Almela M., Mensa J., Sanchez F., Ayats J., Gimenez M., Salvado M., Warnock D.W., Pahissa A., Rodriguez-Tudela J.L., and Barcelona Candidemia Project Study Group. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J. Antimicrob. Chemother. 55 (2005) 194-199
11. Diekema D., Messer S.A., Brueggemann A.B., Coffman S.L., Doern G.V., Herwaldt L.A., and Pfaller M.A. Epidemiology of candidemia: 3-year results from the emerging infection and epidemiology of Iowa organism study. J. Clin. Microbiol. 40 (2002) 1298-1302
12. Godoy P., Tiraboschi I.N., Severo L.C., Bustamante B., Calvo B., Almeida L.P., Matta D.A., and Colombo AL. Species distribution and antifungal susceptibility profile of Candida spp. Bloodstream isolates from Latin American hospitals. Mem. Inst. Oswaldo Cruz 98 (2003) 401-405
13. Goldani L.Z., and Mario P.S.S. Candida tropicalis in a tertiary care hospital. J. Infect. 46 (2003) 155-160
14. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., Herwaldt L., Pfaller M., and Diekema D. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37 (2003) 1172-1177
15. Hajjeh R.A., Sofair A.N., Harrison L.H., Lyon G.M., Arthington-Skaggs B.A., Mirza S.A., Phelan M., Morgan J., Lee-Yang W., Ciblak M.A., Benjamin L.E., Sanza L.T., Huie S., Yeo S.F., Brandt M.E., and Warnock D.W. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42 (2004) 1519-1527
16. Kao A.S., Brandt M.E., Pruitt W.R., Conn L.A., Perkins B.A., Stephens D.S., Baughman W.S., Reingold A.L., Rothrock G.A., Pfaller M.A., Pinner R.W., and Hajjeh R.A. The epidemiology of candidemia in two United States Cities: results of a population-based active surveillance. Clin. Infect. Dis. 29 (1999) 1164-1170
17. Marchetti O., Bille J., Fluckiger U., Eggimann P., Ruef C., Garbino J., Calandra T., Glauser M.P., Tauber M.G., Pittet D., and Fungal Infection Network of Switzerland. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin. Infect. Dis. 38 (2004) 311-320
18. Marr K.A., Seidel K., White T.C., and Bowden R.A. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181 (2000) 309-316
19. McClenny N.B., Fei H., Baron E.J., Gales A.C., Houston A., Hollis R.J., and Pfaller M.A. Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance. Antimicrob. Agents Chemother. 46 (2002) 1325-1328
20. Miller N.S., Dick J.D., and Merz W.G. Phenotypic switching in Candida lusitaniae on copper sulfate indicator agar: association with amphotericin B resistance and filamentation. J. Clin. Microbiol. 44 (2006) 1536-1539
21. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard M27-A2. 2nd ed. (2002), National Committee for Clinical Laboratory Standards, Villanova, PA
22. Nguyen M.H., Clancy C.J., Yu V.L., Yu Y.C., Morris A.J., Snydman D.R., Sutton D.A., and Rinaldi M.G. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J. Infect. Dis. 177 (1998) 425-430
23. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., Powderly W.G., Hyslop N., Kauffman C.A., Cleary J., Mangino J.E., and Lee J. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47 (2003) 3149-3154
24. Park B.J., Arthington-Skaggs B.A., Hajjeh R.A., Iqbal N., Ciblak M.A., Lee-Yang W., Hairston M.D., Phelan M., Plikaytis B.D., Sofair A.N., Harrison L.H., Fridkin S.K., and Warnock D.W. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob. Agents Chemother. 50 (2006) 1287-1292
25. Pfaller M.A., Diekema D.J., Jones R.N., Sader H.S., Fluit A.C., Hollis R.J., Messer S.A., and SENTRY Participant Group. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39 (2001) 3254-3259
26. Pfaller M.A., Messer S.A., Boyken L., Huynh H., Hollis R.J., and Diekema D.J. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob. Agents Chemother. 6 (2002) 3518-3521
27. Pfaller M.A., Diekema D.J., Rex J.H., Espinel-Ingroff A., Johnson E.M., Andes D., Chaturvedi V., Ghannoum M.A., Odds F.C., Rinaldi M.G., Sheehan D.J., Troke P., Walsh T.J., and Warnock D.W. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44 (2006) 819-826
28. Pfaller M.A., Diekema D.J., Colombo A.L., Kibbler C., Ng K.P., Gibbs D.L., and Newell V.A. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program. J. Clin. Microbiol. 44 (2006) 3578-3582
29. Rex J.H., Pfaller M.A., Walsh T.J., Chaturvedi V., Espinel-Ingroff A., Ghannoum M.A., Gosey L.L., Odds F.C., Rinaldi M.G., Sheehan D.J., and Warnock D.W. Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. 14 (2001) 643-658
30. Richet H., Roux P., Des Champs C., Esnault Y., Andremont A., and French Candidemia Study Group. Candidemia in French hospitals: incidence rates and characteristics. Clin. Microbiol. Infect. 8 (2002) 405-412
31. Tortorano A.M., Kibbler C., Peman J., Bernhardt H., Klingspor L., and Grillot R. Candidaemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents. 27 (2006) 359-366
32. Vandeputte P., Larcher G., Berges T., Renier G., Chabasse D., and Bouchara J.P. Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob. Agents Chemother. 49 (2005) 4608-4615
33. Verduyn Lunel F.M., Meis J.F., and Voss A. Nosocomial fungal infections: candidemia. Diagn. Microbiol. Infect. Dis. 34 (1999) 213-220
34. Warren NG., and Hazen K.C. Candida, Cryptococcus, and other yeasts of medical importance. In: Murray P., Baron J., Pfaller A., Tenover F.C., and Yolken R.H. (Eds). Manual of Clinical Microbiology. 7th ed. (1999), American Society for Microbiology, Washington, DC 1184-1199